Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. (Q30574916)
Jump to navigation
Jump to search
scientific article
Language | Label | Description | Also known as |
---|---|---|---|
English | Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. |
scientific article |
Statements
Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer (English)
Celestia S Higano
Catherine M Tangen
Nicholas J Vogelzang
Michael A Carducci
Amir Goldkorn
Benjamin Ely
Louis M Fink
Tong Xu
Przemyslaw Twardowski
Peter J Van Veldhuizen
Neeraj Agarwal
J Paul Monk
Ram H Datar
Mark Garzotto
Philip C Mack
Primo Lara
Maha Hussain
Ian Murchie Thompson
1 reference
1 reference